Coupled with its sizeable financial costs, the documented adverse effects of GnRH agonist therapy – including osteoporosis, fractures, sexual dysfunction, reduced quality of life and cardiovascular disease [8-12] – would argue for conservative rather than widespread use, particularly in settings where clear evidence of benefit is lacking. Here, GNRH1 is linked to cardiovascular disorder.